Introduction: Cancer and atrial fibrillation (AF) are major public health challenges in the United States, with significant mortality risks and a bidirectional relationship that compounds their burden. Despite substantial documentation of their independent mortality trends, data on concomitant cancer- and AF-related mortality trends remain limited. Methods and Results: We analyzed cancer- and AF-related mortality in the U.S. from 1999 to 2019 using CDC WONDER data, focusing on adults aged ≥25 years. Crude and age-adjusted mortality rates (AAMRs) were calculated, and trends were evaluated using Joinpoint regression. A total of 319,480 deaths were identified, with the AAMR increasing from 4.95 in 1999 to 10.01 in 2019 (AAPC: 3.49%). Males exhibited higher AAMRs than females, while Hispanics demonstrated the greatest increase. Geographic disparities were evident, with the highest AAMRs in Vermont, Minnesota, and Rhode Island and the lowest in Arizona, Georgia, and New Mexico. Conclusion: Cancer- and AF-related mortality has risen significantly over two decades, with notable racial, sex-based, and geographic disparities. These findings underscore the need for targeted interventions to address these inequities and mitigate the growing burden of coexisting cancer and AF.

Introduction: Those with cardiac sarcoidosis (CS) are at risk of sudden cardiac death (SCD), which may be prevented using an implantable cardioverter defibrillator (ICD). There is limited data available that follows the post-procedural outcomes of patients with cardiac sarcoidosis (CS) who have had an ICD implanted. Areas Covered: This review will highlight studies that focus on both appropriate and inappropriate therapies in those with an ICD, as well as device complications in this group. There were several variables inclusive of age, gender, ventricular characteristics and findings on cardiac imaging that were investigated and discussed as influencing factors in predicting appropriate and inappropriate therapies. Conclusions: Adverse events in those with an ICD and CS were minimally reported in the literature. Individuals diagnosed with CS are at high risk of ventricular arrhythmia, with comparable rates of appropriate therapy but higher incidence of side effects and inappropriate therapy. The younger average age of CS patients in comparison to other ICD cohorts warrants the need for further, large-scale, prospective trials with periodic interim follow-ups focused on those with this condition.